HIV Diagnoses in New Zealand Hit Record High

Data from the AIDS Epidemiology Group at the University of Otago found that in 2016, New Zealand had the highest number of HIV diagnoses ever made in 1 year since monitoring began in 1985.
In total, there were 244 individuals diagnosed with HIV in 2016. The gay, bisexual, and other men who have sex with men (MSM) population were most affected. Of the 244 individuals diagnosed, 65% were MSM and 17% were heterosexually infected.
The means of infection were not reported for most of the remaining individuals, but 1 person was infected through injecting drug use and 5 were infected through either MSM or injection drug use, according to a press release.
“The increase in the number diagnosed will be affected by the levels of HIV testing of those at risk,” Dr Sue McAllister, leader of the AIDS Epidemiology Group, said in a release. “However, we also found almost half of MSM infected in New Zealand had a relatively high CD4 cell count, which suggests that they have been infected relatively recently. The persisting increase of recent infections over the last 3 years, along with the increase in total diagnoses, suggests a true rise in incidence in recent years.”
Although the emergence of antiretrovirals has changed the face of HIV and AIDS, challenges remain.
“While now treatable, HIV infection remains a lifelong condition with significant implications for individuals and financial cost to the health service,” Dr McAllister said in the release. “It is clear we must tackle this increase in incidence now in order to reverse the trend.
“All the prevention tools available need to be utilized, such as an increasing promotion of condom use, timely testing for HIV after potential exposure, early access to HIV treatment, and screening and treatment for other sexually transmitted infections. Internationally, there is increasing interest in, and use of, new prevention options including giving HIV medication to uninfected people at highest risk of HIV infection, which has also been shown to be effective at prevention infections.”
Pre-exposure prophylaxis (PrEP) is an anti-HIV medication for high-risk patients who are currently HIV-negative. Studies have shown that daily PrEP can reduce the risk of HIV by more than 90% when used consistently. Among people who inject drugs, it reduces the risk of HIV by more than 70%, according to the CDC. Currently, PrEP is not publicly funded or widely available in New Zealand.
In addition to utilizing prevention tools, Dr McAllister stressed that addressing the stigma is also crucial.
“It is important that efforts are made to combat the stigma about HIV and the groups most affected. When this exists, testing could be discouraged and people are less receptive to health promotion messages,” he said.
The AIDS Epidemiology Group is funded by the Ministry of Health to undertake epidemiology surveillance of HIV infection and AIDS in New Zealand, according to the release. It is based in the Department of Preventive and Social Medicine at the Dunedin School of Medicine at the University of Otago.

Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 

Most Popular

Related Articles

Efavirenz exposure (EVF) in utero is being linked to higher risk of neurologic abnormalities in infants and children.
Financial modeling tool shows research and development lacking of new vaccine candidates for HIV, tuberculosis, and malaria.
Top news of the day from across the health care landscape.
Company Profile >
Contributors >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.